Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

If Wall Street can get through January, the signals become a lot friendlier for bulls The S&P 500 Index (SPX) has posted respective gains of 24%, 23%, and 16% over the past three years. Since 1950, ...

Stocks hurtled past tariffs, a government shutdown and AI fears. The stock market recorded stellar year-end returns when markets closed on Wednesday for the last time in 2025. The performance marked ...

The S&P 500 has delivered three consecutive years of double-digit returns only three times since World War II. After similar streaks in the 1990s the market gained for one to two more years before ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Some situations in life are zero-sum. On Super Bowl Sunday, two teams take the field but only one will emerge victorious, Vince Lombardi Trophy in hand. In a presidential election, only one candidate ...

LeBron finishes with 8 points in Lakers win, logs only his 9th game with single-digit scoring; the last one came Jan. 6, 2007. The Associated Press LeBron James finds Rui Hachimura in the corner for ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...